Working… Menu
Trial record 9 of 67 for:    stem cell peripheral arterial disease AND Occlusive

Side Effects of 4 Times Bone Marrow Mono Nuclear Transplantation in Patients With Ischemic Lower Limb

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01480414
Recruitment Status : Completed
First Posted : November 28, 2011
Last Update Posted : December 27, 2012
Information provided by (Responsible Party):
Royan Institute

Brief Summary:
Critical limb ischemia (CLI) results from severe occlusive disease that impairs distal limb perfusion to the point where oxygen delivery is no longer adequate to meet the metabolic needs of the tissue, even under resting conditions. The limits of peripheral artery disease (PAD) compensatory mechanisms, such as distal vasodilatation and collateral formation, have been exceeded at this point. PAD is a widespread disease, affecting up to 15% of all adults older than 55 years. Formation of true new blood vessels, or angiogenesis, and development of collateral vessels from preexisting blood vessels, or arteriogenesis, is important in the pathophysiology of vascular disease. By stimulating these processes the investigators might be able to provide an alternative treatment strategy for patients with lower limb ischemia. In response to tissue injury and remodeling, neovascularization usually occurs via the proliferation and migration of progenitor endothelial cells (EPC) from preexisting vasculature. Indeed, recent studies have shown that bone-marrow mononuclear cell (BM-MNC) implantation increases collateral vessel formation in patients with limb ischemia. So the investigators determine to evaluate the efficacy of repeated MNC transplantation in patients with ischemic lower limb.

Condition or disease Intervention/treatment Phase
Ischemic Ulcer Biological: 4times injection Biological: stem cell transplantation Phase 1 Phase 2

Detailed Description:
In this study we transparent bone marrow derived mononuclear stem cells 4 times to the ischemic limb of 11 patients with PAD.first of all all the patients evaluate by physical examination,PFWD,ABI and serologic tests.then underwent bone marrow aspiration to take sample.In our lab the MNC are separated and divided in to equal of them inject to the ischemic foot and the othr one are freezed and inject after 3weeks.3 weeks after second injection again patient underwent bone marrow aspiration and the same process repeat.then after 4times transplantation,patients are followed up after 1,3,6,9,12 months after injection and evaluate by physical examination,PFWD,ABI and serologic tests.all the data are collected and analysed and the result will be shown.3 patients underwent cell transplantation just one time due to one time bone marrow aspiration.They are followed up after 1,3,6,9,12 months after injection and evaluate by physical examination,PFWD,ABI and serologic the end of the study patients with 4imes injection and 1time injection will be compared.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 20 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Evaluation the Side Effects of Repeated Bone Marrow Derived Mono Nuclear Stem Cells Transplantation in Patients With Lower Limb Ischemic Ulcer
Study Start Date : September 2010
Actual Primary Completion Date : April 2012
Actual Study Completion Date : May 2012

Arm Intervention/treatment
Experimental: 4times injection
the patients with ischemic lower limb ulcer who underwent 4times stem cell injection.
Biological: 4times injection
bone marrow derived mono nuclear stem cell

Experimental: one injection
Patients with peripheral artery disease underwent cell transplantation just one time.
Biological: stem cell transplantation
Mono nuclear stem cell transplantation by intra muscular injection to the ischemic lower limb

Primary Outcome Measures :
  1. side effects [ Time Frame: 3months ]
    evaluation the side effect of cell injection like:allergic reaction,fever,skin eruption,pain increasing,decrease in walking distance,ulcer severity

Secondary Outcome Measures :
  1. PFWD [ Time Frame: 3months ]
    Evaluation the pain free walking distance after cell transplantation.

  2. ABI [ Time Frame: 3months ]
    evaluation the improvement the score of ABI after stem cell transplantation .

  3. size and depth of ulcer [ Time Frame: 3months ]
    evaluation the improvement of ulcer by measuring the size and depth of ulcer in millimeter after transplantation.

  4. Amputation [ Time Frame: 6months ]
    Evaluation the need of limb amputation because of worsening the ulcer after cell injection.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   20 Years to 62 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Ischemic lower limb based on TASK guide line
  • Rutherford score:2,3
  • ABI<0.6
  • Absolute ankle pressure < 60 mmHg
  • Both gender
  • Age:20-62years

Exclusion Criteria:

  • EF<30%
  • Cr>2
  • HbA1c>8%
  • Bone marrow disorders:leukemia
  • Cognitive disorders
  • Infections
  • MI with ST elevation during last month
  • Malignancy
  • Immunologic or rheumatologic disorders

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01480414

Layout table for location information
Iran, Islamic Republic of
Royan Institute
Tehran, Iran, Islamic Republic of
Sponsors and Collaborators
Royan Institute
Layout table for investigator information
Study Chair: Hamid Gourabi, PhD Head of Royan Institute
Study Director: mohammad zafarghandi, MD surgery scientist
Study Director: Nasser Aghdami, MD,PhD head of Royan cell therapy center
Principal Investigator: Behnam Molavi, MD Surgery scientist

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Royan Institute Identifier: NCT01480414     History of Changes
Other Study ID Numbers: Royan-PVD-002
First Posted: November 28, 2011    Key Record Dates
Last Update Posted: December 27, 2012
Last Verified: July 2010
Keywords provided by Royan Institute:
bone marrow mono nuclear stem cell ischemic ulcer
Additional relevant MeSH terms:
Layout table for MeSH terms
Pathologic Processes